Patient's own fat cells transplanted to treat osteoarthritis may be effective

April 16, 2015

Putnam Valley, NY. (Mar. 16, 2015) - Osteoarthritis (OA), a debilitating and painful degenerative disease, strikes an estimated 14 percent of adults 25 years of age and older, a third of adults age 65 and older in the U.S. alone. Those who suffer from OA may one day have a new and effective cell therapy, thanks to a team of Czech researchers who studied the effectiveness of using an OA patient's own adipose (fat) cells in a unique transplant therapy aimed at reducing the symptoms of this prevalent and difficult to treat condition as well as healing some of the damage caused by OA.

The Investigational Review Board of American Naturopathic Research Institute/Naturopathic Oncology Research Institute and local ethics committees-approved study, carried out with 1,114 OA volunteer patients who received autologous (self-donated) fat cell transplants after giving their informed consent, saw their symptoms improved by the therapy. The paper describing the study will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited early e-pub at: http://ingentaconnect.com/content/cog/ct/pre-prints/content-CT-1300_Michalek_et_al

"Adipose-derived cells have potential application in a wide range of clinical disorders, including myocardial infarction, stroke, Crohn's disease, multiple sclerosis (MS), rheumatoid arthritis, and breast augmentation and reconstruction" said Dr. Jaroslav Michalek, of the International Consortium for Cell Therapy and Immunotherapy, and a member of a research team from a number of research facilities and organizations in the Czech Republic. "In this study we evaluated the safety and efficacy of freshly isolated autologous stromal vascular fraction cells (SVF cells). We hypothesized that the SVF cell treatment might contribute to cartilage healing."

Dr. Michalek and his colleagues clarified the use of the term SVF cells by noting that many scientific publications use the term adipose tissue as the source of adipose cells, but that the true source of SVF cells is not adipose but the stroma, the loose connective tissue part of the fat typically obtained by liposuction.

The study followed and evaluated 1,114 patients (median age 62, range 19-94 years; 52.8% male) treated with a single dose of SVF cells isolated from lipoaspirate by a patent pending kit (Cellthera). Patients were followed for between 12 and 54 months with a median of 17.2 months of follow-up. Their evaluations were based on pain, non-steroid analgesic usage, limping, extent of joint movement and stiffness before treatment and at three, six, and 12 months. Hip and knee joints were the most common joints treated and some patients had more than one joint treated.

"No serious side effects, systemic infection or cancer was associated with SVF cell therapy," reported the researchers. "Most patients improved gradually three to 12 months after treatment."

The evaluations demonstrated that at least a 75 percent score improvement was noticed in 63 percent of the patients and at least a 50 percent score improvement was documented in 91 percent of the patients after 12 months, said the researchers. Typically patients in the study consumed large amounts of painkillers for their symptoms. Researchers found that painkiller usage declined dramatically after treatment.

"Obesity and a higher grade of OA were associated with slower healing," said Dr. Michalek.

The researchers noted that there are many advantages to using SVF cells over using bone-marrow derived mesenchymal stem cells (MSCs) to treat OA.The SVF cell therapy also has advantages over several other OA therapies, said the researchers. For example, treating OA with total joint (replacement) arthroplasty (TJA) may not be feasible for some because of their advanced age or general health status. TJA has also been associated with considerable side effects, including myocardial infarction, stroke, systemic infections and death.

"Autologous stromal vascular fraction cell therapy for degenerative osteoarthritis is safe, cost effective and clinically effective, and can lead to an improved quality of life," concluded the researchers. "However, there is no guarantee that this cell therapy can lead to a definite cure for degenerative OA. Future patients receiving SVF will need longer follow-up to answer questions about durability and long term safety of SVF cell therapy."

"Use of the stromal vascular fraction has recently gained attention for being more effective in ameliorating symptoms of various diseases than adipose-derived stem cells alone," said Dr. David Eve, of the Department of Neurosurgery and Brain Repair at the University of South Florida and associate editor of Cell Transplantation. "The large sample size of this study is commendable and further demonstration of the effectiveness and safety of this cell therapy could be achieved with longer follow-up and further exploration of the mode of action."
-end-
Contact: Dr. Jaroslav Michalek, Videnska 101/119, Brno 619 00, Czech Republic.
Email: michalek@iccti.eu
Tel: +420-511-181-555

Citation: Authors: Michalek, J.; Moster, R.; Lukac, L.; Proefrock, K.; Petrasovic, M.; Rybar, J.; Capkova, M.; Chaloupka, A.; Darinskas, A.; Michalek, J. Sr.; Kristek, J.; Travnik, J.; Jabandziev, P.; Cibulka, M.; Holek, M.; Jurik, M.; Skopalik, J.; Kristkova, Z.; Dudasova, Z. Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis Cell Transplant. Appeared or available on-line January 20, 2015.

The Coeditors-in-chief for CELL TRANSPLANTATION are at the Diabetes Research Institute, University of Miami Miller School of Medicine and Center for Neuropsychiatry, China Medical University Hospital, TaiChung, Taiwan. Contact, Camillo Ricordi, MD at ricordi@miami.edu or Shinn-Zong Lin, MD, PhD at shinnzong@yahoo.com.tw or David Eve, PhD or Samantha Portis, MS at celltransplantation@gmail.com

Cell Transplantation Center of Excellence for Aging and Brain Repair

Related Osteoarthritis Articles from Brightsurf:

Major savings possible with app-based osteoarthritis treatment
Osteoarthritis treatment conducted digitally via an app costs around 25% of what conventional care costs, according to a study from Lund University in Sweden published in the research journal PLOS ONE.

New approach to treating osteoarthritis advances
Injections of a natural 'energy' molecule prompted regrowth of almost half of the cartilage lost with aging in knees, a new study in rodents shows.

Bone drug may be beneficial for knee osteoarthritis
Bisphosphonates (a class of drugs that prevent the loss of bone density and used to treat osteoporosis and similar diseases) appear to be safe and beneficial for osteoarthritis patients.

Certain jobs linked to higher risk of knee osteoarthritis
Workers in jobs that typically involve heavy lifting, frequent climbing, prolonged kneeling, squatting, and standing face an increased risk of developing knee osteoarthritis.

App helps reduce osteoarthritis pain
By performing a few simple physical exercises daily, and receiving information about their disease regularly, 500 osteoarthritis patients were able to on average halve their pain in 6 months -- and improve their physical function.

Osteoarthritis can increase your risk for social isolation
In a study published in the Journal of the American Geriatrics Society, researchers examined information from the European Project on OSteoArthritis (EPOSA) study.

High rates of opioid prescriptions for osteoarthritis
Opioids work against severe pain but the risks of side effects and addiction are high.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

3D printing may help treat osteoarthritis
In a Journal of Orthopaedic Research study, scientists used 3D printing to repair bone in the joints of mini-pigs, an advance that may help to treat osteoarthritis in humans.

Finger joint enlargements may be linked to knee osteoarthritis
Heberden's nodes (HNs) are bony enlargements of the finger joints that are readily detectable in a routine physical exam and are considered hallmarks of osteoarthritis.

Read More: Osteoarthritis News and Osteoarthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.